Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae expands test menu to include hundreds of new genes, dozens of new test panels for cancer, cardiology, neuromuscular, pediatrics, and rare disorders

Invitae expands test menu to include hundreds of new genes, dozens of new test panels for cancer, cardiology, neuromuscular, pediatrics, and rare disorders

October 07, 2015

Company announces it exceeded its goal with more than 600 genes in production, commercially launching new panels immediately and throughout the end of 2015 

 

Hosting an investor conference call today at 4:30 p.m. ET 

 

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will release the new content between now and the end of the year. ...

Read more


Invitae announces new education program to accelerate the use of family history and increase awareness of genetic testing

Invitae announces new education program to accelerate the use of family history and increase awareness of genetic testing

September 21, 2015

New survey shows that while celebrity stories drive awareness of cancer and genetics, more engagement is needed among patients, their families and their clinicians

A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers—a significant increase over just a few years ago. Previous research found that in 2010 less than half of the Americans surveyed said they were aware of genetic testing. Dubbed the “Angelina Jolie Effect,” the current data highlight the ...

Read more


Invitae to Present at the 2015 Morgan Stanley Global Healthcare Conference

Invitae to Present at the 2015 Morgan Stanley Global Healthcare Conference

September 10, 2015

Invitae Corporation (NYSE: NVTA) today announced that members of the company’s management team will present at the 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18, 2015 at approximately 8:45 a.m. Eastern / 5:45 a.m. Pacific in New York City.

The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusion of the presentation and will ...

Read more


Invitae and collaborators announce publication of new data showing the clinical actionability of multi-gene panel testing for hereditary breast and ovarian cancer risk in JAMA Oncology

Invitae and collaborators announce publication of new data showing the clinical actionability of multi-gene panel testing for hereditary breast and ovarian cancer risk in JAMA Oncology

August 13, 2015

Invitae Corporation (NYSE: NVTA), a genetic information company, and its collaborators announced the publication of new data describing the clinical actionability of multi-gene testing for hereditary breast and ovarian cancer (HBOC) risk in JAMA Oncology. The study was a collaboration among Massachusetts General HospitalHarvard Medical School, Stanford University, Beth Israel Deaconess Medical Center and Invitae.

In this paper, more than 1,000 patients were tested with multi-gene panels, and the clinical actions that would be ...

Read more


Invitae raises volume guidance, announces second quarter 2015 financial results

Invitae raises volume guidance, announces second quarter 2015 financial results

August 06, 2015

Generated strong volume growth, accelerated R&D to expand beyond cancer
Investing to gain scale and enable long-term profitability
Conference call to be held today at 4:45 pm Eastern / 1:45 pm Pacific

SAN FRANCISCO Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the second quarter ended June 30, 2015. The company has raised its guidance for billable tests delivered in 2015 to 16,000-18,000, up from its previous guidance of 14,000-17,000 billable tests delivered.

“We’re pleased to ...

Read more


Invitae to announce second quarter 2015 financial results and host conference call on August 6, 2015

Invitae to announce second quarter 2015 financial results and host conference call on August 6, 2015

July 23, 2015

SAN FRANCISCO Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its second quarter 2015 financial results on Thursday, August 6, 2015 and will host a conference call that day at 4:45 p.m. ET/1:45 p.m. PT to discuss the financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 85327941.

The ...

Read more


Invitae announces online publication of data comparing traditional and multi-gene panel testing for hereditary breast and ovarian cancer in The Journal of Molecular Diagnostics

Invitae announces online publication of data comparing traditional and multi-gene panel testing for hereditary breast and ovarian cancer in The Journal of Molecular Diagnostics

July 22, 2015

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, and collaborators announced the publication of data directly comparing traditional and multi-gene panel testing in more than 1,000 patients in The Journal of Molecular Diagnostics. The data, published online today, are from a collaboration among Invitae, Massachusetts General Hospital, Harvard Medical School, and the Stanford University School of Medicine. The Journal of Molecular Diagnostics is the official journal of the Association for Molecular ...

Read more


Invitae launches new patient pay price of $475 for its full menu of genetic tests

Invitae launches new patient pay price of $475 for its full menu of genetic tests

June 01, 2015

Company’s goal is to make genetic testing more affordable and accessible

Applies to full menu of testing in cancer, cardiology, neurology, pediatric genetics, hematology and other rare conditions

SAN FRANCISCO, June 1, 2015 – Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price covers all of Invitae’s offerings in cancer, cardiology, neurology, pediatric genetics, hematology and ...

Read more


Invitae and collaborators to present new data at the 2015 American Society of Clinical Oncology Annual Meeting focusing on the clinical utility of multi-gene panel tests for hereditary breast and ovarian cancer

Invitae and collaborators to present new data at the 2015 American Society of Clinical Oncology Annual Meeting focusing on the clinical utility of multi-gene panel tests for hereditary breast and ovarian cancer

May 13, 2015

Study demonstrates that Invitae's multi-gene test yields clinically actionable findings for substantially more patients than does traditional single-gene testing

SAN FRANCISCO – Invitae Corporation (NYSE: NVTA), a genetic information company, announced that new data will be presented during the 51st American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, “Clinical Impact of Multi-Gene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment” (Abstract 1513), will be presented as a poster discussion on Monday, June 1 by Leif ...

Read more


Charcot-Marie-Tooth Association announces educational sponsorship with Invitae

Charcot-Marie-Tooth Association announces educational sponsorship with Invitae

May 13, 2015

Organizations teaming up to increase awareness, improve public education for one of the most common neurological conditions

GLENOLDEN, Pa. and SAN FRANCISCO – The Charcot-Marie-Tooth Association (CMTA) announced today that it has formed an educational sponsorship with Invitae Corporation, a genetic information company. 

Affecting nearly 3 million people worldwide, Charcot-Marie-Tooth (CMT) is a group of inherited disorders that affect the peripheral nerves, which are the nerves outside the brain and spinal cord. There are more than 80 kinds of CMT; ...

Read more